MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

Search

Sage Therapeutics Inc

Deschisă

SectorSănătate

9.16 0.22

Rezumat

Modificarea prețului

24h

Curent

Minim

9.1

Maxim

9.19

Indicatori cheie

By Trading Economics

Venit

34M

-62M

Vânzări

1.2M

14M

EPS

-0.998

Marjă de profit

-442.395

Angajați

353

EBITDA

13M

-67M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-5.56% downside

Dividende

By Dow Jones

Următoarele câștiguri

30 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

85M

571M

Deschiderea anterioară

8.94

Închiderea anterioară

9.16

Sentimentul știrilor

By Acuity

100%

0%

361 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Sage Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 iul. 2025, 15:29 UTC

Principalele dinamici ale pieței

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7 iul. 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7 iul. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 iul. 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7 iul. 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7 iul. 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7 iul. 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7 iul. 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7 iul. 2025, 21:34 UTC

Achiziții, Fuziuni, Preluări

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 iul. 2025, 20:45 UTC

Achiziții, Fuziuni, Preluări

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 iul. 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7 iul. 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7 iul. 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7 iul. 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7 iul. 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 iul. 2025, 16:53 UTC

Câștiguri

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7 iul. 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 iul. 2025, 16:05 UTC

Achiziții, Fuziuni, Preluări

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 iul. 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7 iul. 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 iul. 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7 iul. 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7 iul. 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7 iul. 2025, 15:14 UTC

Achiziții, Fuziuni, Preluări

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7 iul. 2025, 15:00 UTC

Achiziții, Fuziuni, Preluări

GSK Completes Acquisition of Efimosfermin

7 iul. 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7 iul. 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7 iul. 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Comparație

Modificare preț

Sage Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

-5.56% jos

Prognoză pe 12 luni

Medie 8.66 USD  -5.56%

Maxim 12 USD

Minim 5 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSage Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

15 ratings

0

Cumpărare

14

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 7.285Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.